June 02, 2014
NASHVILLE, Tenn- Sarah Cannon, an affiliate of one of the leading healthcare providers in America, Hospital Corporation of America (HCA), announced today that its Chief Medical Officer and Executive Director, Drug Development, Howard A. Burris III, MD, has been named one of OncLive’s 2014 “Giants of Cancer Care.” OncLive, which is the official home of Oncology & Biotech News, OncologyLive and several other industry publications, created the award program to recognize and celebrate individuals who have achieved landmark success within the field of oncology.
“For more than 20 years, Dr. Burris has been devoted to the advancement of therapies for patients through innovative cancer research and care”
Dr. Burris is one of 16 luminaries nationwide selected by oncology peers for his remarkable achievements in research and clinical practice, which includes specific recognition for his initiation of one of the largest investigational drug development programs for cancer.
“For more than 20 years, Dr. Burris has been devoted to the advancement of therapies for patients through innovative cancer research and care,” said Sarah Cannon’s Chief Executive Officer, Dee Anna Smith. “Recognition from this esteemed panel of oncology advisors is an incredible honor – and we are proud to have Dr. Burris guiding our clinical programs, as he has made significant contributions to the development of new agents that have transformed cancer treatment options worldwide.”
Under Dr. Burris’ leadership, the Sarah Cannon Research Institute has conducted more than 130 first-in-man clinical trials and made an impact on more than half of the new cancer therapies approved in the last 10 years. Beyond his cancer research contributions, Dr. Burris oversees the company’s integrated services that pair research with the delivery of physician-led and patient-centric cancer care.
Giants of Cancer Care are chosen by an exclusive advisory board of 29 oncology educators, clinicians and researchers. Advisory Board members have dedicated their valuable time to the program, providing guidance to OncLive as it further develops the program and, most importantly, selects the oncologists who will be named Giants. In evaluating criteria for selection to the inaugural class of Giants, the Advisory Board considered individuals who have made a significant contribution to patient care, clinical trials or translational research.
OncLive Chairman and CEO Mike Hennessy said, “It is our distinct privilege to honor these unsung medical heroes. It is our mission to continue recognizing the leaders in the oncology field for their remarkable achievements in research and clinical practice.”
The 2014 Giants of Cancer Care were announced and honored at an invitation-only reception Friday, May 30 in Chicago. Each Giant will be individually profiled in a special edition of OncologyLive and prominently featured on OncLive.com.
About Sarah Cannon
Sarah Cannon, the cancer institute of the Hospital Corporation of America (HCA), advances science and transforms care in communities across the United States and United Kingdom. While the care service line was launched in 2011, Sarah Cannon has had a rich history in clinical research beginning in 1993 when its research investigators brought clinical trials into the community setting. The global network’s cancer care reach includes individualized patient navigation provided by oncology-trained nurse navigators, experience conducting more than 130 first-in-man clinical trials, more than 850 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network and the first community-based molecular profiling program. Through its programs, Sarah Cannon is providing state-of-the- art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center.
To learn more about Sarah Cannon, go to sarahcannon.com.
OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Urologists in Cancer Care, Oncology Nursing News, and Contemporary Oncology. The mission of OncLive® and its family of publications is to provide oncology professionals with the resources and information they need in order to provide the best care for their patients. The Oncology Specialty Group is a division of Intellisphere, LLC, a leading provider of health care publishing, research and education. To learn more, please visit www.OncLive.com.